Sonazoid
Head & Neck Cancer
The Netherlands Cancer InstitutePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
141 Active assets in the Head & Neck Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 4 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II ImmunityBio, Inc. | Phase 3 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
Carboplatin Rapa Therapeutics LLC | Phase 3 | BB |
Epirubicin Thomas Jefferson University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Sonazoid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →